R01AI164746

Innate immune mechanisms governing subclinical malaria in children - Abstract

Subclinical (asymptomatic) malaria with Plasmodium falciparum (PF) is common in children who live in moderate- to-high transmission areas of sub-Saharan Africa. Although subclinical malaria may be submicroscopic, affected school-age children (ages 8-15 years) often have positive blood smears that include millions of parasites per ml of blood.

While subclinical malaria is typically attributed to acquired adaptive immunity that tightly controls the PF biomass, patent parasitemia (blood smear+) exceeds any reasonable estimate of the pyrogenic threshold. How is it possible to remain without fever and overt malaria symptoms with patent parasitemia?

In contrast to symptomatic malaria, temporally persistent (chronic) subclinical malaria seems to be maintained by a complex balance of pro-inflammatory and anti-inflammatory cytokines and immune cells. The scientific premise of this proposal is that epigenetic modifications of innate immune cells, including blood monocytes (MO), modulate inflammatory pathways underlying subclinical malaria. Furthermore, we hypothesize that an immune homeostasis network involving anti-inflammatory PF-induced type 1 T regulatory cells (TR1) and IL-10 as well as enhanced IL-1RA production suppress innate immune inflammatory pathways.

Subclinical malaria is of high epidemiologic significance as parasitemia persists for months in schoolchildren who serve as the major reservoir of gametocytes required to sustain PF transmission to local Anopheles vectors. Indeed, it is estimated that ~60% of new mosquito infections can be attributed to this demographic.

To test our hypotheses, we will enroll Kenyan schoolchildren (ages 8-15) in a longitudinal cohort study to compare and analyze differences in immune parameters between those with a) chronic subclinical malaria (PF+ smear at baseline and who remain afebrile despite repeatedly smear+ x 16 weeks) relative to b) children who develop febrile clinical malaria up to 2 weeks after an afebrile PF+ smear. The specificity of immune parameters for chronic PF exposure in these cohorts will be interrogated by comparison to age and sex matched children residing in a nearby highlands area where malaria endemicity is ~zero.

PBMC and isolated MO from children will be analyzed by RNA-Seq to determine activated gene expression pathways. We will define the differences in immune cell subsets, the transcription factors that are activated, and their effector cytokine expression profiles using mass cytometry (CyTOF). In addition, we will use chromatin immunoprecipitation (ChIP) DNA sequencing to determine if the epigenomes of children with chronic subclinical malaria are modified in order to silence proinflammatory genes or conversely, to activate anti-inflammatory ones. Finally, we will identify and compare by assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) open chromatin sites in key gene expression pathways in MO from the comparator groups and align these regions with RNA-Seq data from the same child.

The successful completion of this project should give us new and important insights as to the mechanism of subclinical malaria and how this disease state can be modified to facilitate malaria eradication.

Case Western Reserve University

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Cleveland, Ohio 44106 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 311% from $737,656 to $3,030,131.